GLP-1 RAs lower POAG, ocular hypertension risks in T2D patients
The use of glucagon-like peptide 1 receptor agonists (GLP-1 RA), compared with metformin, results in a significant decrease in the incidence of primary open-angle glaucoma (POAG), ocular hypertension, and the need for first-line glaucoma treatments in patients with type 2 diabetes (T2D), reports a study.
